Author

Jean-Pierre Issa

Coriell Institute for Medical Research - Cited by 72,757 - Epigenetics - Cancer - Aging - DNA methylation

Biography

Jean-Pierre Issa is a well-known researcher working in Department of Cancer, Coriell Institute for Medical Research and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
DNA methylation aging clocks: challenges and recommendations
CG Bell, R Lowe, PD Adams, AA Baccarelli, S Beck, JT Bell, ...Genome biology 20, 1-24, 2019201
500
2019
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
G Garcia-Manero, G Roboz, K Walsh, H Kantarjian, E Ritchie, P Kropf, ...The Lancet Haematology 6 (6), e317-e327, 2019201
75
2019
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
X Hu, MR Estecio, R Chen, A Reuben, L Wang, J Fujimoto, ...Nature communications 12 (1), 687, 2021202
34
2021
Whole-organ genomic characterization of mucosal field effects initiating bladder carcinogenesis
T Majewski, H Yao, J Bondaruk, W Chung, S Lee, JG Lee, S Zhang, ...Cell reports 26 (8), 2241-2256. e4, 2019201
33
2019
Microbial Colonization Coordinates the Pathogenesis of a Klebsiella pneumoniae Infant Isolate
JL Pope, Y Yang, RC Newsome, W Sun, X Sun, M Ukhanova, J Neu, ...Scientific Reports 9 (1), 3380, 2019201
28
2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
W Chung, AD Kelly, P Kropf, H Fung, J Jelinek, XY Su, GJ Roboz, ...Clinical epigenetics 11 (1), 1-12, 202
19
2019
S879 Results of ASTRAL-1 study, a phase 3 randomized trial of guadecitabine (G) vs treatment choice (TC) in treatment naïve acute myeloid leukemia (TN-AML) not eligible for …
P Fenaux, M Gobbi, PL Kropf, J Mayer, GJ Roboz, H Döhner, J Krauter, ...HemaSphere 3 (S1), 394-395, 2019201
18
2019
Results from a global randomized phase 3 study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naive (TN) AML Unfit for Intensive Chemotherapy (IC …
GJ Roboz, H Döhner, M Gobbi, PL Kropf, J Mayer, J Krauter, T Robak, ...Blood 134, 2591, 2019201
16
2019
Promoter methylation changes in ALOX12 and AIRE1: novel epigenetic markers for atherosclerosis
JY Kim, BG Choi, J Jelinek, DH Kim, SH Lee, K Cho, SH Rha, YH Lee, ...Clinical Epigenetics 12, 1-13, 2020202
15
2020
Cellular Heterogeneity–Adjusted cLonal Methylation (CHALM) improves prediction of gene expression
J Xu, J Shi, X Cui, Y Cui, JJ Li, A Goel, X Chen, JP Issa, J Su, W LiNature communications 12 (1), 400, 2021202
13
2021
High folic acid intake increases methylation-dependent expression of Lsr and dysregulates hepatic cholesterol homeostasis
D Leclerc, J Jelinek, KE Christensen, JPJ Issa, R RozenThe Journal of Nutritional Biochemistry 88, 108554, 2021202
12
2021
Gestational high fat diet protects 3xTg offspring from memory impairments, synaptic dysfunction, and brain pathology
A Di Meco, J Jelinek, E Lauretti, ME Curtis, JPJ Issa, D PraticòMolecular psychiatry 26 (), 7006-7019, 2021202
11
2021
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy
AM Zeidan, P Fenaux, M Gobbi, J Mayer, GJ Roboz, J Krauter, T Robak, ...Blood, The Journal of the American Society of Hematology 140 (3), 285-289, 2022202
11
2022
Accelerated aging in normal breast tissue of women with breast cancer
S Panjarian, J Madzo, K Keith, CM Slater, C Sapienza, J Jelinek, JPJ IssaBreast Cancer Research 23 (1), 1-14, 2021202
8
2021
The two-hit hypothesis meets epigenetics
JP IssaCancer research 82 (), 116-1169, 2022202
7
2022
Selective CDK9 inhibition by natural compound toyocamycin in cancer cells
S Pandey, R Djibo, A Darracq, G Calendo, H Zhang, RA Henry, ...Cancers 14 (14), 3340, 2022202
5
2022
The roles of DNA demethylases in triple-negative breast cancer
S Panjarian, JPJ IssaPharmaceuticals 14 (7), 628, 2021202
5
2021
Comparative modeling of CDK9 Inhibitors to explore selectivity and structure-activity relationships
P Kirubakaran, G Morton, P Zhang, H Zhang, J Gordon, M Abou-Gharbia, ...bioRxiv, 2020.06. 08.138602, 2020202
4
2020
TET1 and TDG suppress intestinal tumorigenesis by down-regulating the inflammatory and immune response pathways
R Tricarico, J Madzo, G Scher, S Maegawa, J Jelinek, C Scher, ...bioRxiv, 676445, 2019201
3
2019
Hypomethylation in MTNR1B: a novel epigenetic marker for atherosclerosis profiling using stenosis radiophenotype and blood inflammatory cells
JY Kim, J Jelinek, YH Lee, DH Kim, K Kang, SH Ryu, HR Moon, K Cho, ...Clinical Epigenetics 15 (1), 11, 030
2
2023

Referred From: https://scholar.google.com/citations?user=fhHpk68AAAAJ&hl=en

Cited by
Citations 72757
h-index 143
i10-index 353
Recommended Journals
Open Access Journals